Breaking News Instant updates and real-time market news.

SPPI

Spectrum

$21.04

-0.33 (-1.54%)

11:44
09/24/18
09/24
11:44
09/24/18
11:44

Spectrum announces preliminary poziotinib data from Phase 2 study

Spectrum Pharmaceuticals announced preliminary poziotinib data from the University of Texas, MD Anderson Cancer Center Phase 2 non-small cell lung cancer study which were released during an oral presentation at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. The MD Anderson study is the single largest data set of patients with an exon 20 mutation in EGFR or HER2. In the interim analysis presented at the WCLC, the following observations were made: This phase II study demonstrates high anti-tumor activity for poziotinib in metastatic, heavily pretreated EGFR exon 20 mutant NSCLC, a group for which no targeted agents have proven effective to date with best response of PR in 55% of evaluable patients. Median PFS 5.5m; durable responses observed with 6 treated for greater than1year thus far. Compares favorably to historical ORR rates of less than8% approved TKIs and less than19% for standard of care 2L agents. Significant activity also observed in HER2 exon 20-mutant NSCLC with initial responses observed in 50% evaluable patients and median PFS 5.1m. EGFR-related toxicities were manageable and required dose reductions in 60%. Discontinuation due to poor tolerance was rare. Encouraging activity has prompted a confirmatory, international, multicenter study in EGFR and HER2 exon 20 mutant NSCLC patients which is currently enrolling, including a first-line cohort, and development of a separate pan-tumor basket study. The poziotinib NSCLC clinical program for patients with EGFR or HER2 exon 20 insertion mutations currently consists of a Phase 2 investigator-initiated study at The University of Texas, MD Anderson Cancer Center and a Phase 2 pivotal, Spectrum-sponsored, multi-center, global study with active sites in the United States and future centers planned in Canada and Europe. The overall poziotinib clinical development program is focused on four pillars, including previously treated NSCLC, first-line treatment of NSCLC, combination therapy and treatment of other solid tumors.

  • 24

    Sep

  • 01

    Oct

SPPI Spectrum
$21.04

-0.33 (-1.54%)

09/06/18
JEFF
09/06/18
NO CHANGE
Target $25
JEFF
Buy
Spectrum should begin to retrace last week's selloff, says Jefferies
Jefferies analyst Matthew Andrews says the new interim poziotinib data from the MD Anderson Phase 2 non-small cell lung cancer study "don't disappoint." Shares of Spectrum Pharmaceuticals should begin to retrace the drop since last week amid concerns about the Korean poziotinib HER2 data, Andrews tells investors in a research note. The analyst believes the unconfirmed overall response rate of 58% in EGFR and 50% in HER2 are "impressive." He keeps a Buy rating on Spectrum with a $25 price target.
09/06/18
HCWC
09/06/18
NO CHANGE
Target $40
HCWC
Buy
Spectrum price target raised to $40 from $34 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Spectrum Pharmaceuticals to $40 after the company presented at his firm's conference. The analyst remains optimistic about both the stock and the company's pipeline, which he notes includes poziotinib in non-small cell lung cancer and HER2-positive breast cancer and Rolontis in chemotherapy-induced neutropenia. Progress is being made across developmental programs along with upcoming catalysts, White tells investors in a research note. He keeps a Buy rating on Spectrum.
08/31/18
RILY
08/31/18
NO CHANGE
Target $35
RILY
Buy
Spectrum price target raised to $35 from $26 at B. Riley FBR
B. Riley FBR analyst David Buck raised his price target for Spectrum Pharmaceuticals to $36 and keeps a Buy rating on the shares ahead of the company's September 5 data abstract.
06/27/18
RILY
06/27/18
NO CHANGE
Target $26
RILY
Buy
Spectrum takeover report 'plausible,' says B. Riley FBR
Following a report from Bloomberg yesterday that Spectrum Pharmaceuticals is exploring options including a sale of the business amid takeover interest from other drugmakers, B. RIley FBR analyst David Buck told investors in a research note that while he has no confirmation of any takeover interest or sale process, he sees the report as "plausible." Buck, who reiterated a Buy rating, says that he continues to see his $26 per share target based on DCF and 2022E earnings power as "reasonable." Aide from any actual news on a potential transaction or sales process that gets confirmed, he expects further news flow on pipeline drug Rolontis, including a June 29 Spectrum-sponsored conference call and an expected presentation of additional poziotinib data at the World Lung Conference.

TODAY'S FREE FLY STORIES

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:38
10/19/18
10/19
17:38
10/19/18
17:38
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:36
10/19/18
10/19
17:36
10/19/18
17:36
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

, LMT

Lockheed Martin

$328.22

0.21 (0.06%)

17:33
10/19/18
10/19
17:33
10/19/18
17:33
Periodicals
Trump to meet CEOs of Boeing, Lockheed Martin, General Dynamics, Reuters reports »

President Donald Trump…

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

LMT

Lockheed Martin

$328.22

0.21 (0.06%)

BA

Boeing

$356.28

-3 (-0.84%)

GD

General Dynamics

$190.43

-0.76 (-0.40%)

BAESY

BAE Systems

$0.00

(0.00%)

HON

Honeywell

$153.49

-1.73 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

ISR

IsoRay

$0.50

0.0191 (3.98%)

17:25
10/19/18
10/19
17:25
10/19/18
17:25
Syndicate
Breaking Syndicate news story on IsoRay »

IsoRay files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHS

Neuberger Berman High Yield Strategies Fd

$10.55

-0.015 (-0.14%)

17:06
10/19/18
10/19
17:06
10/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Neuberger Berman High Yield Strategies Fd »

Saba Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOC

Biocept

$2.27

-0.04 (-1.73%)

17:04
10/19/18
10/19
17:04
10/19/18
17:04
Syndicate
Breaking Syndicate news story on Biocept »

Biocept files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$726.10

-4.09 (-0.56%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Hot Stocks
AutoZone founder Hyde will not stand for board re-election »

AutoZone announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SACH

Sachem Capital

$4.33

0.02 (0.46%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Syndicate
Breaking Syndicate news story on Sachem Capital »

Sachem Capital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

16:53
10/19/18
10/19
16:53
10/19/18
16:53
Conference/Events
Mirati Therapeutics to hold a conference call »

Dr. Charles Baum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPNE

SeaSpine

$16.58

-0.54 (-3.15%)

16:47
10/19/18
10/19
16:47
10/19/18
16:47
Hot Stocks
Breaking Hot Stocks news story on SeaSpine »

First Light Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

16:46
10/19/18
10/19
16:46
10/19/18
16:46
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

16:40
10/19/18
10/19
16:40
10/19/18
16:40
General news
Breaking General news story on MSCI Italy Index, SPDR S&P 500 ETF Trust, S&P 500 »

Moody's cuts Italy…

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$2.93

-0.02 (-0.68%)

16:39
10/19/18
10/19
16:39
10/19/18
16:39
Hot Stocks
Breaking Hot Stocks news story on Astrotech »

Winn Interests reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$15.43

-1.075 (-6.52%)

16:38
10/19/18
10/19
16:38
10/19/18
16:38
Conference/Events
CytomX Therapeutics to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ICLK

iClick Interactive Asia

$3.41

(0.00%)

16:36
10/19/18
10/19
16:36
10/19/18
16:36
Hot Stocks
Breaking Hot Stocks news story on iClick Interactive Asia »

LIM Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGLS

Tecnoglass

$9.72

(0.00%)

16:35
10/19/18
10/19
16:35
10/19/18
16:35
Syndicate
Breaking Syndicate news story on Tecnoglass »

Tecnoglass files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

16:30
10/19/18
10/19
16:30
10/19/18
16:30
Options
Preliminary option volume of 24.7M today »

Preliminary option volume…

OXM

Oxford Industries

$81.36

-1.68 (-2.02%)

16:28
10/19/18
10/19
16:28
10/19/18
16:28
Conference/Events
Oxford Industries management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HELE

Helen of Troy

$120.52

0.31 (0.26%)

16:26
10/19/18
10/19
16:26
10/19/18
16:26
Conference/Events
Helen of Troy management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CGA

China Green

$0.74

0.0584 (8.57%)

16:21
10/19/18
10/19
16:21
10/19/18
16:21
Hot Stocks
China Green receives NYSE notice regarding late Form 10-K filing »

China Green Agriculture…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.